top of page

Monte Rosa's CEO discusses yesterday's data for MRT-2359 in MYC-driven solid tumors

Markus Warmuth describes PK/PD and clinical observations the company is seeing for this molecular glue protein degradation approach, how safety is shaping up, and a partnership with Roche.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page